This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Won't Yield on Yield

Just about any time a Merck (MRK - Get Report) executive appears before a microphone, presides over a Webcast or attends a financial or medical conference, he or she is asked how safe the dividend is.

The question has been posed ever since Sept. 30, 2004, when Merck pulled the arthritis drug Vioxx from the market, and every time the New Jersey-based drugmaker says its payment isn't in danger.

However, investors can expect this Q&A to continue, perhaps for years, as long as there's uncertainty about potential liabilities of Vioxx.

Wall Street estimates of those liabilities run as high as $55 billion. But the dividend is only part of the financial dilemma for Merck, which is facing several years of declining earnings per share and sales growth.

Merck doesn't have enough new drugs with large-sales potential to offset the lost revenue from big-sellers going off patent, but don't expect any drastic dividend action soon. Merck still has a healthy credit rating.

The company's balance sheet also has been bolstered, thanks to a law signed by President Bush last year that enables companies to repatriate earnings from foreign subsidiaries at sharply reduced tax rates. Merck is repatriating $15 billion.

Still, there's that nagging question. Merck's yield of 5.1% -- second-highest among its peers -- has been attractive to investors willing to wait out the bad times. They might be waiting a while, according to Albert Rauch of A.G. Edwards.

"Our concern is that it will be a long time for the turnaround -- 2008, or even 2009 or 2010," he says.

Stock Support

Cutting the dividend would scare investors because they might interpret the move to mean that Merck fears big Vioxx litigation losses, Rauch says. Merck hasn't established a reserve for potential liabilities, but it has set aside $675 million just for legal expenses.

Big Pharma's Dividends
Company Dividend (Per Share Annual Rate) Share Price Dec. 1 Yield
Bristol-Myers Squibb $1.12 $21.63 5.20%
Merck $1.52 $29.68 5.10%
Pfizer $0.76 $21.38 3.50%
Eli Lilly $1.52 $51.50 3.00%
Abbott $1.10 $37.63 2.90%
Wyeth $1 $41.20 2.40%
Schering-Plough $0.22 $19.05 1.20%

Right now, the dividend is propping up the stock. Rauch says Wall Street is valuing Merck for its ability to maintain the payout rather than its earnings per share performance. Clearly, a dividend cut would send Merck's shares lower. If the price fell too low, Merck could even become a takeover target, says Rauch, who doesn't own shares and whose firm doesn't have an investment banking relationship with the company.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $154.17 -1.40%
BMY $70.76 -0.52%
MRK $54.80 -0.51%
PFE $33.42 -0.83%
SNY $40.38 -1.90%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs